A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies
2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative
Company chart and information is provided by TradingView based on 15-minute-delayed data.
CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.
| Website: | www.cytosorbents.com |
| Email: | avogel@cytosorbents.com |
| Main Phone: | +1 732 329-8885 |
| Address: | 7 Deer Park Drive |
| Address 2: | Suite K |
| State: | NJ |
| City / Town: | Monmouth Junction |
| Country: | US |
| Postal Code: | 08852 |
| Exchange: | NSC |
| CEO: | Phillip P. Chan |
| Employees: | 195 |
| NAICS: | Medical Laboratories(621511) |
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies
2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative
As I write this, the Alerian MLP Index is in the midst of a five-day losing streak and broke below its year-end closing price intra-day today. The index rebounded to close back in the green for
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
